UCB

The CenterWatch Monthly, January 2012

Tuesday, January 3, 2012 11:06 AM

Site landscape shrinking, losing most active PIs

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »

UCB enters strategic partnerships with Parexel and PRA

Thursday, November 17, 2011 10:33 AM

Brussels, Belgium-based UCB has entered into strategic partnerships with Parexel and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.

More... »

Amgen, UCB experiment with NASA

Wednesday, July 6, 2011 01:17 PM

Amgen and UCB are collaborating with the National Aeronautics and Space Administration (NASA) to conduct a pre-clinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis on the final NASA shuttle mission, Space Shuttle Flight STS-135.

More... »

UCB launches research alliance with Harvard University

Wednesday, June 29, 2011 12:22 PM

Brussels-based UCB and Harvard University have officially launched an innovative research alliance in a signing ceremony in Boston attended by his Royal Highness Prince Philippe of Belgium.

More... »

Amgen and UCB report positive results for osteoporosis study

Tuesday, April 26, 2011 01:32 PM

California-based Amgen and Belgium-based UCB reported positive results from their phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). The 12-month phase 2 study is a multi-center, international, randomized, placebo-controlled and parallel-group study.

More... »

UBC-CogState Partnership Short-Lived

Monday, March 9, 2009 07:29 AM

Bethesda, Md.-based contract research organization (CRO) United BioSource Corporation (UBC) has ended its partnership with cognitive testing provider CogState—just seven months after it began.

More... »

Lupus Drug Shows Promise in Phase I/II Trial

Wednesday, August 22, 2007 07:26 AM

UCB and Immunomedics reported positive results from a follow-up phase I/II trial of epratuzumab for the treatment of systemic lupus erythematosus (SLE). Phase I of the trial enrolled 12 subjects with SLE and analyzed the effect of epratuzumab on circulatory B-cell subsets. Results showed that epratuzumab preferentially targets naive and transitional B-cells.

More... »

Trio Offers Webinar Training Series on Adaptive Trials

Wednesday, June 27, 2007 12:13 PM

Maryland-based CRO United BioSource Corporation (UBC), in conjunction with eClinical firm Medidata Solutions, and the adaptive trials tools and modeling company Tessella, have joined together to educate the industry on the use of adaptive clinical trials in drug development. The companies are producing a series of free webinars—six in total—that will feature expertise from industry professionals and regulatory authorities on how to overcome some of the challenges of these studies.

More... »